Dosage Reductions

Recommended RYBREVANT® dose reductions for ARs1

RYBREVANT® (amivantamab) dose reductions for adverse reaction tableRYBREVANT® (amivantamab) dose reductions for adverse reaction table

Recommended LAZCLUZE™ dose reductions for ARs2

Recommended LAZCLUZE™ dose reductions for ARs2

LAZCLUZE™ dose reductions for adverse reactionsRYBREVANT® dose reductions for adverse reactions

Adverse Event Severity Scale3

Based on the Common Terminology Criteria for Adverse Events (CTCAE) v5.0*

Adverse reactions severity breakdown chartAdverse reactions severity breakdown chart
*

CTCAE definition may differ from the Prescribing Information.

†

Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the telephone, managing money, etc.

‡

Self-care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden.

AR, adverse reaction.

Dosage Modifications

Recommended dosage modifications for ARs1,2

Recommended dosage modifications for ARs for RYBREVANT® + LAZCLUZE™

For RYBREVANT® + LAZCLUZE™ refer to both the RYBREVANT® and LAZCLUZE™ recommendations. For RYBREVANT® + chemotherapy or RYBREVANT® as a single agent, refer only to the RYBREVANT® recommendations.

For RYBREVANT® + LAZCLUZE™ refer to both the RYBREVANT® and LAZCLUZE™ recommendations. For RYBREVANT® + chemotherapy or RYBREVANT® as a single agent, refer only to the RYBREVANT® recommendations.

Breakdown of RYBREVANT® adverse reactions, severity, and corresponding dose modificationsRYBREVANT® dose modifications based on adverse reactions and severity

Recommended dosage modifications for ARs for RYBREVANT® in combination with LAZCLUZE™1

When administering RYBREVANT® in combination with LAZCLUZE™, if there is an AR requiring dose reduction after withholding treatment and resolution, reduce the dose of RYBREVANT® first.

Recommended dosage modifications for ARs for RYBREVANT® in combination with carboplatin and pemetrexed1

When administering RYBREVANT® in combination with carboplatin and pemetrexed, modify the dosage of one or more drugs. Withhold or discontinue RYBREVANT® as shown in the table above. Refer to the Prescribing Information for carboplatin and pemetrexed for additional dosage modification information.

ILD, interstitial lung disease; IRR, infusion-related reaction; TEN, toxic epidermal necrolysis; VTE, venous thromboembolism.

RYBREVANT® Proactive Supportive Care Guide PDF coverpdfmobileimage

To learn more about how to manage adverse reactions, download the Proactive Therapy Management Guide

Download the guide

References:

  1. RYBREVANT® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
  2. LAZCLUZE™ [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
  3. US Department of Health and Human Services. National Cancer Institute. Common terminology criteria for adverse events (CTCAE). Version 5.0. Published November 27, 2017. Accessed June 7, 2024. https://ctep.cancer.gov/
    protocoldevelopment/electronic_applications/
    docs/CTCAE_v5_Quick_Reference_5x7.pdf
  4. US Department of Health and Human Services. National Cancer Institute. Common terminology criteria for adverse events (CTCAE). Version 5.0. Published November 27, 2017. Accessed June 7, 2024. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf